AI Insight
This international phase 3 randomized controlled trial (ROAM/EORTC-1308) compared adjuvant radiotherapy versus observation in patients with WHO grade 2 atypical meningioma following complete surgical resection. The study found that adjuvant radiotherapy significantly reduced meningioma recurrence compared to observation alone. The authors conclude that radiotherapy should be considered as a treatment option when preventing recurrence is prioritized over potential delayed adverse effects, with decisions made through individual patient consultation.
Why it matters
This trial provides high-level evidence to guide clinical decision-making for atypical meningioma management, a tumor type with significant recurrence risk. The findings support the use of adjuvant radiotherapy to reduce recurrence rates, though treatment decisions must balance efficacy against potential long-term radiation side effects based on individual patient values and circumstances.
Understand the Science
Our findings suggest that adjuvant radiotherapy should be considered in patients with atypical meningioma after complete surgical resection of atypical meningioma when the prevention of recurrence is valued higher than the potential delayed adverse effects of radiotherapy. This practice will benefit patients by reducing meningioma recurrence. Decisions should be based on individual discussion with the patient.